San Diego, California – On 19 June 2017 Joe Damond, Executive Vice President of BIO, signed a Memorandum of Understanding for Cooperation (MOU) with Mr. Mike Dethick, Managing Director of the China R&D-based Pharmaceutical Association Committee (RDPAC). RDPAC is a non-profit organization under the China Association of Enterprises with Foreign Investment (CAEFI) and has a membership of 38 multi-national companies with pharmaceutical R&D capability in China.
The signing is a reaffirmation of the exisiting MOU and is expected to enable the two associations to collaborate more closely on activities and issues of common interest, as well as to further develop partnerships in China.
Joe Damond, EVP of BIO, said: “This MOU continues the longstanding relationship between BIO and RDPAC and will allow us to deepen our cooperative efforts to advance advocacy and outreach for the global biotech industry in China, and to highlight the value of biotechnology in benefiting society and addressing health challenges.”
It is anticipated that the cooperation will focus on several areas including expert-level exchange, research, and workshops. “The bio-industry has been designated as one of China’s seven strategic emerging industries (SEI) by the government. The agreement between RDPAC and BIO represents an important commitment to support China in creating an environment that promotes innovation and greater integration of China into the global biopharmaceutical ecosystem. ” Mike Dethick, Managing Director of RDPAC said.